Clinical Trial Details
— Status: Not yet recruiting
Administrative data
NCT number |
NCT06435143 |
Other study ID # |
H24-00304 |
Secondary ID |
|
Status |
Not yet recruiting |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
June 1, 2024 |
Est. completion date |
November 30, 2024 |
Study information
Verified date |
May 2024 |
Source |
University of British Columbia |
Contact |
Lisa J Maks, MN |
Phone |
604-816-6523 |
Email |
lmaks[@]providencehealth.bc.ca |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
The focus of this study will be early stage pressure ulcers, which can quickly progress to
stage 3, 4 or deep tissue injury The proposed study explores the feasibility of intermittent
electrical stimulation (IES),Prelivia, a novel, non-invasive technology in the management of
stage 1 and 2 pressure ulcers.
Description:
Pressure ulcers (also known as pressure injuries or bedsores) constitute a major morbidity in
critically ill patients due to immobilization, deranged tissue perfusion, and poor nutrition.
It is estimated that the prevalence of pressure injuries is 2.2 to 23.9 percent or higher,
depending on the hospital environment, significantly contributing to nosocomial risk and
healthcare costs.
Particularly, they are one of the most common complications among people with limited
mobility is increased pressure on certain areas of the body causing reduced blood flow and
damage to the skin.
There has been extensive research that shows electrical stimulation can be useful in pressure
ulcer treatment. (Arora et al, 2020) (5) Electrical stimulation is provided by an electrical
current, which can be applied in many ways.
The study intervention applies Intermittent Electrical Stimulation (IES) to the affected area
through surface electrodes. The device invokes muscle contractions for 10 seconds every 10
minutes, emulating the subconscious adjustments performed by able- bodied individuals in
response to discomfort when seated or lying down. Animal studies demonstrate that IES reduces
internal pressure at bone-muscle interfaces (the hypothesized mechanism for injury
development), increases tissue oxygenation in surrounding areas, and reduces or eliminates
deep tissue injury in muscles subjected to prolonged loading (Appendix A). (6) (L. Solis et
al., 2008) (7) Clinical studies support the safety, feasibility, and general acceptability of
gluteal IES in human participants. (Appendix B) (Ahmetovic et al., 2015) (8) (Kane et al.,
2017) (9) This technology has been studied and has shown, with strong evidence, the capacity
of IES to prevent sacral and ischial pressure injuries.
Prelivia uses RHT's patented Intermittent Electrical Stimulation (IES) technology which
counteracts damaging tissue compression and increases blood flow to parts of the body that
are at risk. Prelivia acts by mimicking the physiological micro-contractions that normally
occur in mobile individuals when they fidget or shift their weight. Prelivia works by
restoring subconscious muscle contractions and movements, or a 'fidgeting' movement that
able-bodied individuals are able do. These muscle contractions increase tissue perfusion -
the process in which metabolic waste is removed and fresh blood, oxygen, and nutrients are
brought into the tissue. The target muscles(such as the glutei maximi) are electrically
stimulated for 10 seconds every 10 minutes to restore adequate tissue perfusion to the
surrounding tissue.
The system consists of a battery-powered stimulator (Prelivia Stimulator) and disposable
hydrogel electrodes. Prelivia's streamlined design, simple application, and low cost make it
the ideal addition to existing standard of care procedures.
Prelivia is the only device on the market that addresses poor circulation and low oxygenation
in compressed areas. Current pressure injury preventative interventions rely on either
temporarily relieving pressure (nurses turn patients every 2 hrs) , creams, or redistributing
pressure (specialized mattresses, cushions, etc.). However, neither of these interventions
restore blood circulation, tissue oxygenation, or tissue perfusion.
Primary objective: To evaluate users' interaction with the device, safety and tolerability by
patients when wearing Prelivia IES during management of pressure injuries stage 1 and 2
during their stay in the hospital, up to 30 days, until patient death or discharge whatever
comes first.
Secondary objective : Compare the status and healing time of stage 1 and 2 pressure injuries
matched with the historic controls, via retrospective data review. Historic controls will
involve consideration of various factors:
Patients with documented stage 1 and 2 pressure injuries matched according to the age range,
gender, location of pressure injury(ies), Body mass Index and comorbidities.
Data will be requested from the Providence Healthcare Integrated Health informatics Datalab.
Exploratory objective: Develop high level health economic model for pressure injury cost
savings.